Skip to Content

Johnson & Johnson JNJ

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

J&J Highlights Strong Drug Innovation at Investor Day, Setting Up Steady Long-Term Growth

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Johnson & Johnson’s pharmaceutical investor day highlighted several key pipeline drugs, but we don’t expect any major changes to our fair value estimate based on the update. However, the strong pipeline innovation presented at the meeting reinforces our view of the firm’s wide moat.

Read Full Analysis

Company Profile

Business Description

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total sales are generated in the United States.

Contact
One Johnson and Johnson Plaza
New Brunswick, NJ, 08933
T +1 732 524-0400
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Sep 30, 2021
Fiscal Year End Jan 3, 2022
Stock Type Slow Growth
Employees 136,400

Related